Gold Fields (GFI) Stock Falls Alongside Gold Prices

NEW YORK (TheStreet) -- Shares of Gold Fields  (GFI) were declining 6.76% to $5.17 on heavy trading volume late Tuesday afternoon as lower gold prices weighed on the South African gold miner. 

Gold for December delivery was down 0.84% to $1,315.90 per ounce on the COMEX earlier today. 

The precious metal is trading lower as the dollar strengthens on speculation that the Federal Reserve will soon hike interest rates. 

"We believe there is over an 80% chance that the Fed will increase the interest rate one more time this year," Naeem Aslam, chief market analyst with ThinkMarkets, told MarketWatch. "If the U.S. [nonfarm payrolls] number shows a solid reading on Friday, we are expecting September to become more volatile and as of now, there is roughly a 35% chance that the Fed could increase the rate."

Dollar-denominated commodities such as gold become more expensive and less desirable to foreign buyers when the greenback is strong. 

About 6.92 million shares of Gold Fields have been traded so far today vs. the stock's average trading volume of roughly 5.03 million shares a day. 

Separately, TheStreet Ratings team rates the stock as a "sell" with a ratings score of D+.

Gold Fields's weaknesses include its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and feeble growth in its earnings per share.

You can view the full analysis from the report here: GFI

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author. 

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing